Michael Kauffman, Chief Executive Officer at Karyopharm Therapeutics Inc. (KPTI), sold 20,000 shares at $14.76 ($294K) on 2019-11-11, disclosed to the SEC on 2019-11-12.
Open-market sale of $294k KPTI by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.63 | 10,000 | $146K | 49.8% |
| 2 | $14.76 | 10,000 | $148K | 50.2% |
| Total | $14.70 avg | 20,000 | $294K | 100% |
| Filing → |
| KPTI | SELL | 2022-03-02 | $128K | — | Filing → |
| KPTI | SELL | 2022-02-22 | $440K | — | Filing → |
| KPTI | SELL | 2022-02-09 | $266K | — | Filing → |